Interview with Thea Pharma’s Susan Benton about Eye Care and the FDA Approval of Iyuzeh

In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Susan Benton, Country Manager at Thea Pharma, an eye care company that focuses on developing innovative eye care treatments to help further the future of ophthalmic treatment.

Thea Pharma recently won FDA approval for its latest eye care product Iyuzeh for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Iyuzeh is the first and only preservative-free formulation of the medication latanoprost in the US. 

To talk more about the new FDA approval for Iyuzeh and about the great work being done at Thea Pharma, tune in to hear this informative and insightful interview with Susan Benton, who has more than 25 years of global commercial and business development experience in ophthalmic pharmaceuticals, and has been responsible for the launch and commercialization of more than 15 products over the course of her career.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured